Cargando…
Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy
Vulvovaginal atrophy (VVA) and dryness are common symptoms of the decline in endogenous production of estrogen at menopause and often result in dyspareunia. Yet while 10% to 40% of women experience discomfort due to VVA, it is estimated that only 25% seek medical help. The main goals of treatment fo...
Autores principales: | Kingsberg, SA, Kellogg, S, Krychman, M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2971714/ https://www.ncbi.nlm.nih.gov/pubmed/21072280 |
Ejemplares similares
-
Management of Vaginal Atrophy: Implications from the REVIVE Survey
por: Wysocki, Susan, et al.
Publicado: (2014) -
Reviewing the options for local estrogen treatment of vaginal atrophy
por: Lindahl, Sarah H
Publicado: (2014) -
Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast
por: Soe, Lin H, et al.
Publicado: (2013) -
Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
por: Wurz, Gregory T, et al.
Publicado: (2014) -
WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history
por: Kingsberg, Sheryl A., et al.
Publicado: (2019)